BTIG analyst Kambiz Yazdi maintained a Buy rating on Rapport Therapeutics, Inc. yesterday and set a price target of $65.00.

TipRanks Welcomes a New ETF – NYSE:RANK

• TipRanks has entered a new arena in the investing world, powering the index of an ETF based on its unique data now trading under the ticker RANK on the NYSE.
• RANK tracks the performance of the TipRanks US Momentum Analysts Index, a rules-based index of 50 large U.S. companies.

Kambiz Yazdi has given his Buy rating due to a combination of factors, including the significant unmet need in acute bipolar mania and the differentiated profile of RAP-219. He highlights that current therapies rely heavily on dopamine-based antipsychotics and older mood stabilizers, which leave a large subset of patients either inadequately controlled or unable to tolerate treatment, thereby creating a meaningful opportunity for a novel approach.

Yazdi emphasizes that RAP-219’s selective TARPγ8 modulation of AMPARs offers a mechanistically distinct, non-dopaminergic strategy that aligns with the neurocircuitry implicated in mania and could extend time to relapse due to its long half-life, a feature he views as commercially important. With Phase 2 data in bipolar mania expected in 4Q26 and a valuation framework combining a long-dated DCF and peak-sales multiple supporting an unchanged $65 price target, he sees a favorable risk–reward balance and thus reiterates a Buy rating on Rapport Therapeutics, Inc.

According to TipRanks, Yazdi is a 5-star analyst with an average return of 29.0% and a 69.23% success rate. Yazdi covers the Healthcare sector, focusing on stocks such as Praxis Precision Medicines, AbSci, and Kazia Therapeutics.